OVERVIEW

7th Translational Research E-Conference: Myelodysplastic Syndromes is organized by European School of Haematology (ESH) and will be held from Jan 28 - 31, 2021.

Description:
Until recently, information on the biology of MDS and options available for its treatment were limited. A lot of data has accumulated in recent years on the pathophysiology of MDS, particularly on the role of somatic mutations (including in very early disease phase), haploinsufficiency for certain genes, and the impact of abnormalities of the microenvironment. Prognostic factors of the disease have also been refined, with the revised IPSS, and new factors like somatic mutations. Treatment approaches are improving, although not at the same speed, and only allogeneic stem cell transplantation remains potentially curative.

Learning Objectives:
• Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics, but also through the use of new tools, mainly molecular analysis.
• Improve ability to analyze prognostic factors, including new ones (revised IPSS, molecular analysis).
• Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell transplantation.
• Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials. Diagnostic, prognostic and therapeutic issues will be presented by the faculty and ample time will be devoted to discussion with delegates.

Note: The Virtual platform will remain open from January 19 until March 2, 2021 so that participants can view and review the programme’s full scientific content at times convenient to them.